NCT05130593

Brief Summary

The purpose of this study is to make a bar from the soy-protein Russian Tarragon complex (PMI-5011/Nutrasorb) that is safe and acceptable for consumption, and to test the blood levels of plasma bioactive (DMC-2) after ingestion of the bar. The PMI-5011/Nutrasorb comes from a plant source called Artemisia dracunculus. This plant has a long history of medicinal (health) and culinary (food) use and has been reported as effective as a traditional treatment for diabetes in various parts of the world.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 6, 2021

Completed
19 days until next milestone

Study Start

First participant enrolled

October 25, 2021

Completed
29 days until next milestone

First Posted

Study publicly available on registry

November 23, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2022

Completed
1 year until next milestone

Results Posted

Study results publicly available

November 18, 2023

Completed
Last Updated

November 18, 2023

Status Verified

November 1, 2023

Enrollment Period

1 year

First QC Date

October 6, 2021

Results QC Date

October 24, 2023

Last Update Submit

November 14, 2023

Conditions

Keywords

tarragon

Outcome Measures

Primary Outcomes (1)

  • Palatability of Bar

    Participants were asked to rate the bar on a visual analog scale to indicate their impression of its visual appearance, smell, taste, texture, aftertaste, and overall pleasantness. The scale range for each attribute is 0-100 with higher scores equating to a better outcome.

    Test Day (immediately after taste-testing the bar)

Secondary Outcomes (3)

  • Levels of Plasma BIoactive (DMC-2) Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.

    10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption

  • Levels of Serum Glucose Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.

    10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption

  • Measurement of Blood Levels of Serum Insulin Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.

    10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption

Study Arms (1)

Nutrasorb bar evaluation

Participants in Phase 1 will taste test the bar for acceptability. Participants in Phase 2 will consume the bar and have blood samples drawn for measurement of safety parameters (glucose and insulin) and bioactive compounds (DMC-2).

Dietary Supplement: Nutrasorb bar

Interventions

Nutrasorb barDIETARY_SUPPLEMENT

250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings

Nutrasorb bar evaluation

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

healthy males and females aged 18-50 with a body mass index between 20-30 kg/m2

You may qualify if:

  • Healthy males or females between 18 and 50 years of age inclusive.
  • Body mass index between 20-30 kg/m2.

You may not qualify if:

  • Pregnant or currently lactating.
  • Taking any prescription medications.
  • Taking any over-the-counter medications that cannot be stopped for test days.
  • Allergic to any ingredients contained in the bar.
  • Other conditions or situations that would interfere with the study or the participant's safety as determined by the investigators.
  • Participants in Phase 1 of the study may not participate in Phase 2 of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pennington Biomedical Research Center

Baton Rouge, Louisiana, 70808, United States

Location

Results Point of Contact

Title
Jennifer C Rood, PhD
Organization
Pennington Biomedical Research Center

Study Officials

  • Jennifer C Rood, Ph.D.

    Pennington Biomedical Research Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 6, 2021

First Posted

November 23, 2021

Study Start

October 25, 2021

Primary Completion

October 31, 2022

Study Completion

October 31, 2022

Last Updated

November 18, 2023

Results First Posted

November 18, 2023

Record last verified: 2023-11

Locations